Class I Phosphatidylinositol 3-Kinases
"Class I Phosphatidylinositol 3-Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits.
| Descriptor ID |
D058534
|
| MeSH Number(s) |
D08.811.913.696.620.500.100.100 D08.811.913.696.620.500.200.100 D12.776.476.162
|
| Concept/Terms |
Class I Phosphatidylinositol 3-Kinases- Class I Phosphatidylinositol 3-Kinases
- Class I Phosphatidylinositol 3 Kinases
- Class I Phosphatidylinositol 3-Kinase
- Class I Phosphatidylinositol 3 Kinase
- Phosphatidylinositol 3-Kinase, Class I
- Phosphatidylinositol 3 Kinase, Class I
|
Below are MeSH descriptors whose meaning is more general than "Class I Phosphatidylinositol 3-Kinases".
Below are MeSH descriptors whose meaning is more specific than "Class I Phosphatidylinositol 3-Kinases".
This graph shows the total number of publications written about "Class I Phosphatidylinositol 3-Kinases" by people in this website by year, and whether "Class I Phosphatidylinositol 3-Kinases" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 11 | 11 |
| 2013 | 3 | 8 | 11 |
| 2014 | 0 | 15 | 15 |
| 2015 | 3 | 22 | 25 |
| 2016 | 6 | 19 | 25 |
| 2017 | 3 | 14 | 17 |
| 2018 | 5 | 7 | 12 |
| 2019 | 16 | 5 | 21 |
| 2020 | 6 | 11 | 17 |
| 2021 | 10 | 7 | 17 |
| 2022 | 1 | 10 | 11 |
| 2023 | 0 | 12 | 12 |
| 2024 | 4 | 5 | 9 |
| 2025 | 1 | 1 | 2 |
Below are the most recent publications written about "Class I Phosphatidylinositol 3-Kinases" by people in Profiles.
-
Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer. JAMA Netw Open. 2025 Feb 03; 8(2):e2461899.
-
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation. Nat Commun. 2025 Jan 09; 16(1):525.
-
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024 Dec; 25(12):e629-e638.
-
Multi-disciplinary team approach for pediatric hemimegalencephaly: Insights from a single institutional case series. Epilepsia Open. 2024 Dec; 9(6):2510-2517.
-
POU2F2 activates the Akt/mTOR signalling pathway and enhances B lymphocyte function during diabetic kidney disease by promoting PIK3CD transcription. Nephrology (Carlton). 2024 Dec; 29(12):825-837.
-
Pulmonary artery mass with PIK3CA mutation after orthotopic heart transplantation. J Cardiothorac Surg. 2024 Oct 01; 19(1):558.
-
Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study. Cancer Res Commun. 2024 06 27; 4(6):1597-1608.
-
Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome. Blood Adv. 2024 06 25; 8(12):3092-3108.
-
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proc Natl Acad Sci U S A. 2024 Apr 23; 121(17):e2321898121.
-
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia. Cancer Discov. 2024 Feb 08; 14(2):240-257.